BELLADONNA AlKALOIDS WITH PHENOBARBITAL TABLETS

BELLADONNA ALKALOIDS WITH PHENOBARBITAL - atropine sulfate, hyoscyamine sulfate, scopolamine hydrobromide and phenobarbital tablet 
West-ward Pharmaceutical Corp

Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.

----------

DESCRIPTION

BELLADONNA ALKALOIDS WITH PHENOBARBITAL TABLETS

Rx Only

            Each tablet contains:

            Atropine Sulfate, USP……………………………….0.0194 mg

            Hyoscyamine Sulfate, USP…………………………..0.1037 mg

            Scopolamine Hydrobromide, USP………………….. 0.0065 mg

            Phenobarbital, USP…………………………………. 16.2 mg

Inactive ingredients: Anhydrous Lactose, Calcium Stearate, Colloidal Silicon Dioxide, Corn Starch, and Microcrystalline Cellulose.

CLINICAL PHARMACOLOGY

This drug combination provides natural belladonna alkaloids in a specific, fixed ratio combined with phenobarbital to provide peripheral anticholinergic/antispasmodic action and mild sedation.

INDICATIONS AND USAGE

                INDICATIONS AND USAGE:

            Based on a review of this drug by the National Academy of Sciences-

            National Research Council and/or other information, FDA has

            Classified the following indications as “possibly” effective:

            For use as adjunctive therapy in the treatment of irritable bowel

            Syndrome (irritable colon, spastic colon, mucous colitis) and

            acute enterocolitis.

            May also be useful as adjunctive therapy in the treatment of duodenal ulcer. IT HAS NOT BEEN SHOWN CONCLUSIVELY WHETHER ANTICHOLINERGIC/ANTISPASMODIC DRUGS AID IN THE HEALING OF A DUODENAL ULCER, DECREASE THE RATE OF RECURRENCES OR PREVENT COMPLICATIONS.

CONTRAINDICATIONS

Glaucoma, obstructive uropathy (for example, bladder neck obstruction due to prostatic hypertrophy); obstructive disease of the gastrointestinal tract (as in achalasia, pyloroduodenal stenosis, etc.); paralytic ileus, intestinal atony of the elderly or debilitated patient; unstable cardiovascular status in acute hemorrhage; severe ulcerative colitis especially if complicated by toxic magacolon; myasthenia gravis; hiatal hernia associated with reflux esophagitis.

Belladonna alkaloids with phenobarbital tablets are contraindicated in patients with known hypersensitivity to any of the ingredients. Phenobarbital is contraindicated in acute intermittent porphyria and in those patients in whom phenobarbital produces restlessness and/or excitement.

WARNINGS

In the presence of a high environmental temperature, heat prostration can occur with belladonna alkaloids (fever and heatstroke due to decreased sweating).

Diarrhea may be an early symptom of incomplete intestinal obstruction, especially in patients with ileostomy or colostomy. In this instance treatment with this drug would be inappropriate and possibly harmful.

Belladonna alkaloids with phenobarbital tablets may produce drowsiness or blurred vision. The patient should be warned, should these occur, not to engage in activities requiring mental alertness, such as operating a motor vehicle or other machinery, and not to perform hazardous work.

Phenobarbital may decrease the effect of anticoagulants, and necessitate larger doses of the anticoagulant for optimal effect. When the phenobarbital is discontinued, the dose of the anticoagulant may have to be decreased.

Phenobarbital may be habit forming and should not be administered to individuals known to be addiction prone or to those with a history of physical and/or psychological dependence upon drugs.

Since barbiturates are metabolized in the liver, they should be used with caution and initial doses should be small in patients with hepatic dysfunction.

PRECAUTIONS

General

Use with caution in patients with: autonomic neuropathy, hepatic or renal disease, hyperthyroidism, coronary heart disease, congestive heart failure, cardiac arrhythmias, tachycardia, and hypertension.

Belladonna alkaloids may produce a delay in gastric emptying (antral stasis) which would complicate the management of gastric ulcer.

Theoretically, with overdosage, a curare-like action may occur.

Carcinogenesis, Mutagenesis, Impairment of Fertility

Carcinogenesis, mutagenesis. Long-term studies in animals have not been performed to evaluate carcinogenic potential.

Pregnancy Category C

 Animal reproduction studies have not been conducted with belladonna alkaloids with phenobarbital tablets. It is not known whether belladonna alkaloids with phenobarbital tablets can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Belladonna alkaloids with phenobarbital tablets should be given to a pregnant woman only if clearly needed.

Nursing Mothers

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when belladonna alkaloids with phenobarbital tablets are administered to a nursing mother.

ADVERSE REACTIONS

Adverse reactions may include xerostomia; urinary hesitancy and retention; blurred vision; tachycardia; palpitation; mydriasis; cycloplegia; increased ocular tension; loss of taste sense; headache; nervousness; drowsiness; weakness; dizziness; insomnia; nausea; vomiting; impotence; suppression of lactation; constipation; bloated feeling; musculoskeletal pain; severe allergic reaction or drug idiosyncrasies, including anaphylaxis, urticaria and other dermal manifestations; and decreased sweating. Elderly patients may react with symptoms of excitement, agitation, drowsiness, and other untoward manifestations to even small doses of the drug. Phenobarbital may produce excitement in some patients, rather than a sedative effect. In patients habituated to barbiturates, abrupt withdrawal may produce delirium or convulsions.

OVERDOSAGE

The signs and symptoms of overdose are headache, nausea, vomiting, blurred vision, dilated pupils, hot and dry skin, dizziness, dryness of the mouth, difficulty in swallowing, CNS stimulation. Treatment should consist of gastric lavage, emetics, and activated charcoal. If indicated, parenteral cholinergic agents such as physostigmine or bethanechol chloride, should be added.

DOSAGE AND ADMINISTRATION

The dosage of belladonna alkaloids with phenobarbital tablets should be adjusted to the needs of the individual patient to assure symptomatic control with a minimum of adverse effects.

Adults: One or two tablets three or four times a day according to condition and severity of symptoms.

HOW SUPPLIED

Belladonna Alkaloids with Phenobarbital Tablets are supplied as: White, round, scored, compressed tablets imprinted “West-ward 140”.

             Bottles of 8 tablets.

             Bottles of 30 tablets.

             Bottles of 50 tablets.

             Bottles of 100 tablets.

             Bottles of 1000 tablets.

             Bottles of 5000 tablets.

Store at 20-25°C (69-77°F) [See USP Controlled Room Temperature]. Protect from light and moisture.

Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.

Manufactured by:

West-ward Pharmaceutical Corp.

Eatontown, NJ 07724

Revised April 2005

LABEL PRINCIPAL DISPLAY PANEL

 BELLADONNA  ALKALOIDS WITH PHENOBARBITAL TABLETS
NDC: 0143-1140-51

0.1037/0.0194/0.0065/16.2 mg

Belladonna Alkaloids with Phenobarbital Tablets


BELLADONNA ALKALOIDS WITH PHENOBARBITAL 
belladonna alkaloids with phenobarbital tablet
Product Information
Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:0143-1140
Route of AdministrationORALDEA Schedule    
Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
ATROPINE SULFATE (ATROPINE) ATROPINE SULFATE0.0194 mg
HYOSCYAMINE SULFATE (HYOSCYAMINE) HYOSCYAMINE SULFATE0.1037 mg
SCOPOLAMINE HYDROBROMIDE (SCOPOLAMINE) SCOPOLAMINE HYDROBROMIDE0.0065 mg
PHENOBARBITAL (PHENOBARBITAL) PHENOBARBITAL16.2 mg
Inactive Ingredients
Ingredient NameStrength
ANHYDROUS LACTOSE 
CALCIUM STEARATE 
SILICON DIOXIDE 
STARCH, CORN 
CELLULOSE, MICROCRYSTALLINE 
Product Characteristics
ColorWHITEScore2 pieces
ShapeROUNDSize9mm
FlavorImprint Code Ww;140
Contains    
Packaging
#Item CodePackage DescriptionMultilevel Packaging
1NDC:0143-1140-101000 TABLET (1000 TABLET) in 1 BOTTLE, PLASTICNone
2NDC:0143-1140-515000 TABLET (5000 TABLET) in 1 BOTTLE, PLASTICNone

Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
UNAPPROVED DRUG OTHER01/01/198005/23/2012

Labeler - West-ward Pharmaceutical Corp (001230762)

Revised: 08/2012 West-ward Pharmaceutical Corp